title: Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India.
abstract: We report two cases, one male (33 years) and a female (14 years), that developed Post-Kala-azar Dermal Leishmaniasis (PKDL) after successful treatment for visceral leishmaniasis (VL) or Kala-azar with AmBisome, the lipid complex of Amphotericin B. Both cases presented with hypo-pigmented macular lesions all over the body. The patients responded well to AmBisome after treatment with three courses. This first ever case report from India indicates that possibly there is no effective drug for VL until date, which can prevent post-treatment development of PKDL.
authors.affiliation: Department of Clinical Medicine, Rajendra Memorial Research Institute of Medical Sciences, Agamkuan, Patna, India.
authors.forename: V N R
authors.initials: VN
authors.lastname: Das
authors.forename: K
authors.initials: K
authors.lastname: Pandey
authors.forename: D
authors.initials: D
authors.lastname: Singh
authors.forename: C
authors.initials: C
authors.lastname: Forwood
authors.forename: C S
authors.initials: CS
authors.lastname: Lal
authors.forename: P
authors.initials: P
authors.lastname: Das
mesh_terms: D000293:Adolescent; D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D004197:Disease Reservoirs; D005260:Female; D006801:Humans; D007194:India; D007893:Leishmania donovani; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy / Q000469:parasitology*; D007898:Leishmaniasis, Visceral / Q000150:complications* / Q000188:drug therapy / Q000469:parasitology; D008297:Male
chemical_list: D000981:Antiprotozoal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B